BioEntrepreneurship – Intellectual property strategy

BioEntrepreneurship

More BioEntrepreneurship building blocks were gained in last Monday’s BioEntrepreneurship session with an overview of IP in the industry.

Lynda Kurdyduk reviewed the criteria for patentability and how to protect your IP. Anita Nador followed with a discussion of ownership and inventorship. Just because you collaborated on something, do you have any rights to the IP? Important questions for many of you working in research groups in Universities and hospitals. During the second half of the session, Andre Uddin, a seasoned biotech investor, explained what investors are looking for in IP. Konrad Powel-Jones gave examples of how a company he works with strategically developed their IP, and Tom Corr, using University of Toronto as an example, reviewed how tech transfer offices handle IP spun out their institution.

There’s been a lot of discussion flying around MaRS these days about IP:

• Our Global CONNECT blogger discussed the conflicting views of IP policy among speakers at the commercialization conference.
• MaRS’ Ross Wallace shared the idea of a Harvard business prof who suggests researchers adopt software’s IP-less “open source” model in order to accelerate collaboration and innovation.
• Veronika Litinski describes a nascent, but growing, speculative market developing around the trade of “IP”. All of a sudden non-exploited IP is of greater interest to investors and has commercial value.

Where do you stand on the debate? Can innovation really move ahead when researchers don’t share their discoveries in a timely and open manner? Can industry flourish in an “open source” model? Or are we yet again just defining the stark differences between the business and research worlds, and never the twain shall meet?

Regardless, until the discussion is resolved, talk your tech transfer office before you publish if you think you have something of commercial interest!

See you January 15th when we start with a less controversial, but nonetheless critical, topic of Regulatory Affairs. Have a great holiday break!

Downloads

• Linda Kurdyduk’s Presentation (PDF)
• Andre Uddin’s Presentation (PDF)
• Konrad Powell-Jones’ Presentation (PDF)
• Tom Corr’s Presentation (PDF)
• Anita Nador’s Presentation (PDF)
• Session presentation – Dial-up connection (mp4)
• Session presentation – Broadband connection (mp4)

*Please note that you will need a player such as Quicktime (free) to view the mp4 files and Acrobat (free) to view the PDF slides.

Related Blogs

 

BioEntrepreneurship – Market assessment: great new product or just really cool science?
BioEntrepreneurship: Market Assessment After last month’s general overview session on the business of biotech, this month saw the focus of BioEntrepreneurship narrow down on the subject of market

BioEntrepreneurship: The business of biotech
BioEntrepreneurship At last night’s opening BioEntrepreneurship seminar, Dr Lynne Zydowsky, a seasoned industry consultant from California, gave us an in-depth view of the main drivers of toda

Entrepreneurship 101 : An introduction to commercializing university/hospital technologies
Entrepreneurship 101 Dr. Tom Corr of Innovations at the University of Toronto introduced attendees to the role that technology transfer officers play in commercializing institutional technologies. H

Mind to market
Mind to Market Do you notice that every time you ask a good question, the answer arrives very quickly? Call it serendipity, or selective perception (as in the answer was there all along but I didn&#

IP education
Last week, Arshia Tabrizi of Tabrizi Law Office spoke at the CIBC Presents Entrepreneurship 101 lecture about the various forms of intellectual property and how they can be commercially exploited. No

Top ten legal mistakes made by entrepreneurs
Boston Legal: lawyers in pants originally uploaded by LordKhan Written by a Harvard Business School professor who specializes in Entrepreneurial Management, this list covers the legal aspects of en

Tags: biotechnology, commercialization, entrepreneurship, ip, nina chagnon, strategy, tech transfer